What Does Oyster Point Pharma Do?

Total employees230
HeadquartersPrinceton
Founded2015

Oyster Point Pharma, Inc. was a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for ophthalmic diseases. Their flagship product, TYRVAYA® (varenicline solution) Nasal Spray, gained FDA approval as the first and only nasal spray for treating the signs and symptoms of dry eye disease. Founded in 2015, Oyster Point Pharma made significant contributions to eye care before its acquisition by Viatris Inc. in January 2023. This strategic acquisition integrated Oyster Point's promising pipeline and its commercialized product, TYRVAYA®, into Viatris's expanding global healthcare portfolio, particularly bolstering its new ophthalmology franchise.

Where Is Oyster Point Pharma's Headquarters?

HQ Function

The Princeton headquarters served as the central locus for Oyster Point Pharma's corporate operations, research and development oversight, clinical program management, and commercialization strategy.

Notable Features:

Located within the Carnegie Center office park, the headquarters offered a professional environment conducive to biotech operations. Specific unique architectural details of their leased suite are not widely publicized, with the emphasis likely on functional office and support spaces for R&D.

Work Culture:

Oyster Point Pharma was known for fostering a dynamic, innovative, and collaborative work environment. The culture was mission-driven, with employees dedicated to advancing scientific research and bringing novel treatments to patients suffering from ocular diseases.

HQ Significance:

The Princeton, New Jersey headquarters was strategically significant due to its location within a dense ecosystem of pharmaceutical companies, research institutions, and a skilled talent pool, facilitating collaborations and growth.

Values Reflected in HQ: The headquarters aimed to reflect the company's core values of scientific excellence, innovation, and a patient-first approach, by providing a functional and collaborative environment for its team.

Location:

Before its acquisition by Viatris, Oyster Point Pharma's operational and commercial focus was predominantly on the United States market, highlighted by the FDA approval and launch of TYRVAYA® Nasal Spray. While its research and development efforts considered global scientific advancements, its direct commercial presence and infrastructure were concentrated in the U.S. Following the acquisition, its products and development pipeline became part of Viatris's extensive global operations.

Street Address:

902 Carnegie Center, Suite 260

City:

Princeton

State/Province:

New Jersey

Country:

USA

Where Else Does Oyster Point Pharma Operate Around the World?

N/A

Address: N/A

N/A

Buying Intent Signals for Oyster Point Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Oyster Point Pharma? Meet the Executive Team

As of April 2025, Oyster Point Pharma' leadership includes:

Jeffrey Nau, Ph.D., M.M.S. - President and Chief Executive Officer
Daniel Lochner, CFA - Chief Financial Officer
John Snisarenko - Chief Commercial Officer
Lokesh Tantuwaya, M.D., M.B.A., M.S. - Chief Medical Officer
Michael Campbell - Chief Legal Officer and Corporate Secretary

Who's Investing in Oyster Point Pharma?

Oyster Point Pharma has been backed by several prominent investors over the years, including:

New Enterprise Associates (NEA)
Versant Ventures
Invus
Vida Ventures
Flying L Partners
KCK Group

What Leadership Changes Has Oyster Point Pharma Seen Recently?

Hire2
Exits3

In the 12-18 months leading up to and including its acquisition by Viatris in January 2023, Oyster Point Pharma experienced key executive appointments and subsequent departures as part of the integration. Notably, a new CMO and CLO were hired in mid-2022. The acquisition resulted in the transition or departure of most of the legacy Oyster Point Pharma executive team.

Departures

Jeffrey Nau, Ph.D., M.M.S., Jeffrey Nau departed as President and CEO following the acquisition of Oyster Point Pharma by Viatris Inc.
Daniel Lochner, CFA, Daniel Lochner departed as Chief Financial Officer following the acquisition by Viatris Inc.
John Snisarenko, John Snisarenko departed as Chief Commercial Officer following the acquisition by Viatris Inc.

New Appointments:

Lokesh Tantuwaya, M.D., M.B.A., M.S., Lokesh Tantuwaya was appointed as Chief Medical Officer, strengthening the company's clinical leadership prior to acquisition.
Michael Campbell, Michael Campbell joined as Chief Legal Officer and Corporate Secretary, enhancing legal and corporate governance capabilities prior to acquisition.

What Technology (Tech Stack) Is Used byOyster Point Pharma?

Discover the tools Oyster Point Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Oyster Point Pharma Email Formats and Examples

Prior to its acquisition by Viatris, Oyster Point Pharma typically utilized common corporate email formats. The most prevalent pattern was [first_initial][last]@oysterpointrx.com. These formats are now historical as employee communications are managed through Viatris.

[first_initial][last]@oysterpointrx.com

Format

jdoe@oysterpointrx.com

Example

75%

Success rate

What's the Latest News About Oyster Point Pharma?

Oyster Point Pharma / PR NewswireOctober 18, 2021

Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for Dry Eye Disease

Oyster Point Pharma announced U.S. FDA approval for TYRVAYA (varenicline solution) Nasal Spray for treating the signs and symptoms of dry eye disease, marking it as the first and only nasal spray for this indication....more

Oyster Point Pharma / Business WireNovember 16, 2021

Oyster Point Pharma Announces U.S. Launch of TYRVAYA™ Nasal Spray

Oyster Point Pharma announced the U.S. commercial launch of TYRVAYA™ (varenicline solution) Nasal Spray, making the innovative treatment for dry eye disease available to patients by prescription....more

Viatris Inc. / PR NewswireNovember 7, 2022

Viatris Announces Strategic Acquisition of Oyster Point Pharma

Viatris Inc. announced a definitive agreement to acquire Oyster Point Pharma as part of a strategy to establish a new ophthalmology franchise. The deal was valued at approximately $415 million in cash upfront for Oyster Point Pharma shareholders....more

Viatris Inc. / Business WireJanuary 4, 2023

Viatris Completes Acquisition of Oyster Point Pharma

Viatris Inc. announced the successful completion of its acquisition of Oyster Point Pharma, Inc. This transaction officially integrated Oyster Point's assets, including TYRVAYA®, into Viatris, launching Viatris's new ophthalmology franchise....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Oyster Point Pharma, are just a search away.